MEETING ABSTRACT
Cancer immunoediting: Molecular pathways to possible novel therapeutic interventions
Robert D. Schreiber
Cancer Immunity 8 Suppl. 2 : 1 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Molecules regulating the immunosurveillance of tissues
Adrian Hayday, Mike Girardi, Bob Tigelaar, Julie Lewis, Martin Woodward, Jessica Strid and Susannah Barbee
Cancer Immunity 8 Suppl. 2 : 2 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Cancer immunoediting: Recent progress in elimination and equilibrium
Mark J. Smyth, Janelle Sharkey, Jeremy B. Swann, Paul Bolitho and Michele W. L. Teng
Cancer Immunity 8 Suppl. 2 : 3 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Balancing tumor immunity and inflammation
Glenn Dranoff
Cancer Immunity 8 Suppl. 2 : 4 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Shaping an efficient adaptive immune microenvironment in human cancer
Wolf H. Fridman
Cancer Immunity 8 Suppl. 2 : 5 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Is an anticancer immune response mandatory for therapeutic success?
Laurence Zitvogel, Lionel Apetoh, François Ghiringhelli, Fabrice André, Antoine Tesniere and Guido Kroemer
Cancer Immunity 8 Suppl. 2 : 6 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Lymphocyte homeostasis and tumor-specific immunity during immune reconstitution
Hy Levitsky
Cancer Immunity 8 Suppl. 2 : 7 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
A general mechanism for anti-tumor therapy based on Fc receptor engagement
Jeffrey V. Ravetch
Cancer Immunity 8 Suppl. 2 : 8 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Immunologic impact of anti-CTLA-4 antibody
Padmanee Sharma
Cancer Immunity 8 Suppl. 2 : 9 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Antigen presentation and the T-cell response
Michael J. Bevan
Cancer Immunity 8 Suppl. 2 : 10 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Molecular nature of the antigenic entity transferred from antigen donor cell to antigen presenting cells during cross presentation
Pramod K. Srivastava and Manish Garg
Cancer Immunity 8 Suppl. 2 : 11 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Control of tumor immunity by the microenvironment: Overcoming the endothelial barrier
Gunter J. Hämmerling
Cancer Immunity 8 Suppl. 2 : 12 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Open sesame: The endothelin (B) receptor mediates the tumor endothelial barrier to T-cell homing
George Coukos
Cancer Immunity 8 Suppl. 2 : 13 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Targeting a stromal cell protease inhibits tumor growth
Ellen Puré, Joseph Kissil and Angelica Santos
Cancer Immunity 8 Suppl. 2 : 14 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Checkpoint blockade in tumor therapy: New insights and opportunities
James P. Allison
Cancer Immunity 8 Suppl. 2 : 15 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Myeloid-derived suppressor cells in cancer
Vincenzo Bronte
Cancer Immunity 8 Suppl. 2 : 16 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
The hypoxia-adenosinergic protection of tumors from anti-tumor T lymphocytes
Michail V. Sitkovsky
Cancer Immunity 8 Suppl. 2 : 17 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
PD-1, PD-L1 and their ligands: Regulating the balance between T cell activation and tolerance
Arlene H. Sharpe
Cancer Immunity 8 Suppl. 2 : 18 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Updates in adoptive T cell therapy
Carl June, Chrystal Paulos, Carmine Carpenito, Michael Milone, Nicole Aqui, Aaron Rapoport, Richard Carroll and James Riley
Cancer Immunity 8 Suppl. 2 : 19 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Targeting tumors with genetically enhanced T lymphocytes
Michel Sadelain
Cancer Immunity 8 Suppl. 2 : 20 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Adoptive T cell therapy: Back to the future
Cassian Yee
Cancer Immunity 8 Suppl. 2 : 21 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Potential biomarkers of immune activation in ipilimumab-treated patients with advanced melanoma
David Berman
Cancer Immunity 8 Suppl. 2 : 22 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Identification of immunogenic markers in pancreatic and ovarian cancer by seromics
Sacha Gnjatic
Cancer Immunity 8 Suppl. 2 : 23 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Identification of antibody responses induced in patients with biochemically recurrent and castration-resistant prostate cancer receiving GVAX immunotherapy for prostate cancer
Kristen Hege, T. Harding, M. Nguyen, K. Koprivnikar, G. Huan-Tu, J. Ma, N. Sacks, E. Small and K. Jooss
Cancer Immunity 8 Suppl. 2 : 24 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
New response criteria for immunotherapy to capture response patterns in advanced melanoma patients treated with ipilimumab: Results from two phase II trials
Jedd Wolchok
Cancer Immunity 8 Suppl. 2 : 25 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Harmonized T cell monitoring assays as biomarkers for immunotherapy trials: A data driven approach by the CIMT Immunoguiding Program ("CIP")
Cecile Gouttefangeas, C.M. Britten, S. Attig, T.M.S. Køllgaard, A. Letsch, A. Mander, C. Ottensmeier, M.J.P. Welters, S.H. van der Burg and the CIMT-Monitoring Panel
Cancer Immunity 8 Suppl. 2 : 26 (15 December 2008) >Abstract >PDF

MEETING ABSTRACT
Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment
Frederic Lehmann, Jamila Louahed, Swann Gaulis, Olivier Gruselle and Vincent Brichard
Cancer Immunity 8 Suppl. 2 : 27 (15 December 2008) >Abstract >PDF